Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
Summary
GlobalData’s new report, “Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global tumor markers market. The report provides market landscape, competitive landscape and market trends information on the tumor markers market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.
While tumor markers have been part of the global cancer diagnostics market since the 1960s, their popularity as therapeutic targets has only risen in the last few decades, primarily due to the increasing prevalence and mortality related to cancer. Cancer is currently the second leading cause of death in most developed countries of the world such as the US, the UK and so on, and is one of the most researched disease areas in the pharmaceutical and biotechnology industry. The global tumor markers market was estimated at $1 billion in 2010 and is expected to grow at a CAGR (compound annual growth rate) of over 6% till 2017. The tumor markers market is poised for rapid growth as researchers approach major technological breakthroughs in tumor diagnosis and therapy, the discovery of new specific antigens, and the genetic basis of cancer. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, the early detection of tumors, and monitoring biological responses to cancer therapy.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
Reasons to buy
Summary
GlobalData’s new report, “Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global tumor markers market. The report provides market landscape, competitive landscape and market trends information on the tumor markers market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.
While tumor markers have been part of the global cancer diagnostics market since the 1960s, their popularity as therapeutic targets has only risen in the last few decades, primarily due to the increasing prevalence and mortality related to cancer. Cancer is currently the second leading cause of death in most developed countries of the world such as the US, the UK and so on, and is one of the most researched disease areas in the pharmaceutical and biotechnology industry. The global tumor markers market was estimated at $1 billion in 2010 and is expected to grow at a CAGR (compound annual growth rate) of over 6% till 2017. The tumor markers market is poised for rapid growth as researchers approach major technological breakthroughs in tumor diagnosis and therapy, the discovery of new specific antigens, and the genetic basis of cancer. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, the early detection of tumors, and monitoring biological responses to cancer therapy.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.
- Qualitative analysis of key market trends, market drivers, and restraints by each category within tumor markers market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Fujirebio Inc., bioMérieux SA and Beckman Coulter.
Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the tumor markers market globally.
- Design and develop your product development, marketing and sales strategies.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the tumor markers market landscape? - Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global tumor markers market and the factors shaping it.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 GlobalData Report Guidance
3 DISEASE OVERVIEW: CANCER
3.1 Etiology
3.2 Types of cancers
3.2.1 Classification by Histology
3.2.2 Cancer Types by Site
3.3 Cancer Signs and Symptoms
3.4 Cancer Diagnosis
3.5 Epidemiology
4 TUMOR MARKERS OVERVIEW
4.1 Tumor Markers: Technology Overview
4.1.1 Introduction
4.1.2 Types of Tumor Markers
4.1.3 Applications
5 TUMOR MARKERS: GLOBAL MARKET CHARACTERIZATION
5.1 Tumor Markers Market, Global, Revenue ($m), Historic, 2003 − 2010
5.2 Tumor Markers Market, Global, Revenue ($m), Forecast, 2010 − 2017
5.3 Tumor Markers, Key Market Trends
5.3.1 Increasing Investments by Private Equity (PE) /Venture Capital (VC) Firms in Startups is Driving Innovation and Market Growth
5.3.2 Novel Tumor Markers Makes Diagnostic Test for Ovarian Cancer More Efficient
5.4 Tumor Markers, Market Dynamics
5.4.1 Market Drivers
5.4.2 Market Restraints
5.5 Tumor Markers Market, Opportunities and Unmet Needs
5.5.1 Opportunities: Highly Fragmented Market to Provide a Significant Opportunity for Big Tumor Marker Manufacturers
5.5.2 Unmet Needs
6 TUMOR MARKERS MARKET, BY COUNTRY, REVENUE ($M), 2003 – 2017
6.1 Tumor Markers Market, The US, Revenue ($m), Historic, 2003–2010
6.2 Tumor Markers Market, The US, Revenue ($m), Forecast, 2010–2017
6.3 Tumor Markers Market, Canada, Revenue ($m), Historic, 2003–2010
6.4 Tumor Markers Market, Canada, Revenue ($m), Forecast, 2010–2017
6.5 Tumor Markers Market, The UK, Revenue ($m), Historic, 2003-2010
6.6 Tumor Markers Market, The UK, Revenue ($m), Forecast, 2010-2017
6.7 Tumor Markers Market, Germany, Revenue ($m), Historic, 2003-2010
6.8 Tumor Markers Market, Germany, Revenue ($m), Forecast, 2010-2017
6.9 Tumor Markers Market, France, Revenue ($m), Historic, 2003- 2010
6.10 Tumor Markers Market, France, Revenue ($m), Forecast, 2010-2017
6.11 Tumor Markers Market, Italy, Revenue ($m), Historic, 2003-2010
6.12 Tumor Markers Market, Italy, Revenue ($m), Forecast, 2010-2017
6.13 Tumor Markers Market, Spain, Revenue ($m), Historic, 2003-2010
6.14 Tumor Markers Market, Spain, Revenue ($m), Forecast, 2010-2017
6.15 Tumor Markers Market, Japan, Revenue ($m), Historic, 2003-2010
6.16 Tumor Markers Market, Japan, Revenue ($m), Forecast, 2010-2017
6.17 Tumor Markers Market, China, Revenue ($m), Historic, 2003-2010
6.18 Tumor Markers Market, China, Revenue ($m), Forecast, 2010-2017
6.19 Tumor Markers Market, India, Revenue ($m), Historic, 2003-2010
6.20 Tumor Markers Market, India, Revenue ($m), Forecast, 2010-2017
6.21 Tumor Markers Market, Australia, Revenue ($m), Historic, 2003-2010
6.22 Tumor Markers Market, Australia, Revenue ($m), Forecast, 2010-2017
6.23 Tumor Markers Market, Brazil, Revenue ($m), Historic, 2003-2010
6.24 Tumor Markers Market, Brazil, Revenue ($m), Forecast, 2010-2017
7 TUMOR MARKERS MARKET: COMPETITIVE LANDSCAPE
7.1 Tumor Markers Market, Key Company Share (%), 2010
7.2 Abbott Laboratories (Abbott)
7.2.1 Company Overview
7.2.2 Marketed Products
7.2.3 Pipeline Products
7.2.4 SWOT Analysis
7.3 F. Hoffman-La Roche
7.3.1 Company Overview
7.3.2 Marketed Products
7.3.3 Pipeline Products
7.3.4 SWOT Analysis
7.4 Fujirebio Inc.
7.4.1 Company Overview
7.4.2 Marketed Products
7.4.3 SWOT Analysis
7.5 bioMérieux S.A.
7.5.1 Company Overview
7.5.2 Marketed Products
7.5.3 Pipeline Products
7.5.4 SWOT Analysis
7.6 Beckman Coulter
7.6.1 Company Overview
7.6.2 Marketed Products
7.6.3 Pipeline Products
7.6.4 SWOT Analysis
8 GLOBAL TUMOR MARKERS MARKET: OTHER MAJOR COMPANIES
8.1 Clarient Inc.
8.1.1 Company Overview
8.1.2 Marketed Products
8.1.3 Pipeline Products
8.2 Siemens Healthcare
8.2.1 Company Overview
8.2.2 Marketed Products
8.2.3 Pipeline Products
8.3 DiaSorin SpA
8.3.1 Company Overview
8.3.2 Marketed Products
8.4 QIAGEN N.V.
8.4.1 Company Overview
8.4.2 Marketed Products
8.4.3 Pipeline Products
8.5 Xeptagen SpA
8.5.1 Company Overview
8.5.2 Marketed Products
8.5.3 Pipeline Products
9 GLOBAL TUMOR MARKERS MARKET: STRATEGIC PIPELINE ASSESSMENT
9.1 Tumor Markers Market: Pipeline Products summary
9.2 Tumor Markers, Pipeline Products by Development Stage, Global, 2010
9.3 Tumor Markers Market, Pipeline Products by Therapy Area, Global, 2010
10 TUMOR MARKERS- IMPORTANT PIPELINE PRODUCTS BY COMPANY
10.1 F.Hoffman La Roche'
10.1.1 Integrated Modular Analytics cyfra21-1/NSE Test
10.2 bioMérieux S.A.
10.2.1 EHT Dx 12
10.2.2 EHT Dx 13
10.3 Siemens Healthcare
10.4 Epigenomics AG
10.4.1 Epi proColon-mSEPT9
10.4.2 Lung Cancer Screening Test
10.5 Xeptagen SpA
10.5.1 DCP-IgM Liver cancer Test
10.5.2 Multi-Marker biochip
10.5.3 SCCA–IgM Pulmonary cancer test
10.6 AdnaGen Inc.
10.6.1 AdnaTest BreastCancer
10.6.2 AdnaTest ColonCancer
10.7 QIAGEN N.V.
10.7.1 BRaf Test-Colon Cancer
10.7.2 EGFR Assay-Lung Cancer
10.8 Quanterix corporation
10.8.1 AccuPSA Test
10.9 Rosetta Genomics
10.9.1 miRNA Based Diagnostic Test For Breast Cancer
10.10 Oncomethylome Sciences
10.10.1 Cervical cancer diagnostic test
10.10.2 InformDx - Lung Cancer test
10.11 Onconome Inc.
10.11.1 ColoMark CCSA-4 Serum Assay
10.12 Source MDx
10.12.1 Aggressive Cancer Stratification–Prostate Cancer
10.12.2 Precision Profile-Prostate Cancer Early Detection
10.13 Trovagene, Inc.
10.13.1 AML/NPM1-Bone Marrow/Blood
10.14 Mitomics Inc.
10.14.1 Bladder Cancer-Diagnostic Test
10.15 Glycozyme.
10.15.1 Breast cancer Biomarker Assay
10.16 Neogenix Oncology Corporation
10.16.1 Diagnostic Marker-Colorectal Cancer
10.17 Exiqon A/S
10.17.1 Colon Cancer Recurrence Test
10.17.2 miRNA Test-Endometrial Cancer
10.18 China Sky One Medical, Inc.
10.18.1 Semi-quantitative test for uterine cancer
10.18.2 Liver Cancer Diagnostic Kit
10.19 Advanced Cell Diagnostics
10.19.1 Breast Cancer Test
10.20 Zetiq Technologies Ltd
10.20.1 CellDetect for Cervical Cancer
10.21 Biomoda, Inc.
10.21.1 Cypath-bladder cancer diagnostic assay
10.22 Predictive Biosciences. Inc.
10.22.1 Biomarker mGSTP1-Prostate Cancer
10.23 Power3 Medical Products, Inc
10.23.1 BC-SeraPro Assay
10.24 DiaGenic ASA
10.24.1 BCtect
10.24.2 Breast Cancer Screening Test
10.25 Protagen AG
10.25.1 Breast Cancer-Early Diagnosis assay
10.26 BioMarCare Technologies Ltd.
10.26.1 Breast PARpanel
10.27 Akers Biosciences, Inc.
10.27.1 Breath PulmoHealth Check
10.28 Allegro Diagnostics, Inc.
10.28.1 BronchoGen
10.29 MabCure, Inc.
10.29.1 Diagnostic Test-Breast Carcinoma
10.30 Cangen Biotechnologies, Inc.
10.30.1 Early Stage Lung Cancer Diagnostic test
10.31 Exosome Diagnostics, Inc.
10.31.1 EGFR Cancer Gene Mutation test
10.32 Exagen Diagnostics, Inc.
10.32.1 eXagenBC(ER/PR+)
10.33 Martell Biosystems, Inc
10.33.1 FACTT-Breast cancer assay
10.34 Miraculins Inc.
10.34.1 P2V Prostate Cancer Test
10.34.2 Gastric Cancer Diagnostic Test
10.35 NorDiag ASA
10.35.1 Genefec III
10.36 A&G Pharmaceutical, Inc.
10.36.1 GP88 Blood Diagnostic Test
10.37 Expression Pathology Inc.
10.37.1 HER2 Assay for Breast Cancer
10.38 Milagen, Inc
10.38.1 Immunoassay - Colon Cancer
10.39 IncellDx, Inc.
10.39.1 IncellDx Breast Cancer Test
10.40 Gene Express, Inc.
10.40.1 Lung Cancer Diagnostic Assay
10.41 GenomicTree Inc
10.41.1 MDScan Cervical Cancer Screening Test
10.42 BIOCRATES Life Sciences AG
10.42.1 Metabolomic Biomarker Assay-Cancer
10.43 Health Discovery Corporation
10.43.1 Molecular diagnostic test-pancreatic cancer
10.44 Gene Express, Inc.
10.44.1 Molecular Diagnostic Tests for Bladder Cancer
10.45 IRIS International, Inc.
10.45.1 NADiA ProsVue
10.46 Everist Genomics, Inc.
10.46.1 OncoDefender-CRC
10.47 Orion Genomics LLC
10.47.1 Orion Colorectal Cancer Risk Test
10.48 Correlogic Systems, Inc.
10.48.1 OvaCheck
10.49 Arrayit Corporation
10.49.1 OvaDx
10.50 Protagen AG
10.50.1 Ovarian Cancer-Early Diagnosis Assay
10.51 HealthLinx Limited
10.51.1 OvPlex 2nd Generation
10.52 Strategic Diagnostics Inc.
10.52.1 Pancreatic Cancer Assay
10.53 HistoRx, Inc.
10.53.1 PI3K Multimarker Assay
10.53.2 PROGENSA PCA3 Assay
10.54 Correlogic Systems, Inc.
10.54.1 ProstaCheck
10.55 AnalizaDx, LLC
10.55.1 Prostate Cancer Biomarker Test
10.56 Ambrilia Biopharma Inc.
10.56.1 PSP94 Immunoassay
10.57 BioCurex Inc
10.57.1 RECAF Blood Test
10.58 Fermiscan Holdings Limited
10.58.1 The Fermiscan Test
10.59 Nanosphere, Inc.
10.59.1 Verisens Ultra-Sensitive PSA Assay
11 GLOBAL TUMOR MARKERS MARKET: DEALS LANDSCAPE
11.1 Global Tumor Markers Market: Deals Overview
11.2 Global Tumor Markers Market: Key Acquisitions
11.2.1 Vivakor Enters Into Memorandum of Understanding to Merge with Resolution Biomedical
11.2.2 GE Healthcare Acquires Clarient
11.2.3 Danaher to Acquire Beckman Coulter Inc
11.2.4 Myriad Genetics to Acquire Novel Technology from Melanoma Diagnostics
11.2.5 Fujirebio Acquires Innogenetics from Abbott Laboratories
11.3 Global Tumor Markers Market: Partnership Deals
11.3.1 UCL Business Enters Into a Licensing Agreement with Becton Dickinson
11.3.2 Rosetta Genomics Enters Into an Agreement with Carmel Medical Center
11.3.3 Transgene Signs an Agreement with Beckman Coulter Inc
11.3.4 Neogenix Oncology Enters an Agreement with IRCCS San Raffaele Pisana
11.3.5 Vermillion Enters Into an Agreement with Quest Diagnostics
11.3.6 BioMérieux Enters into a Co-Development Agreement with Biocartis
11.3.7 Epigenomics Enters Into an Agreement with Pronto Diagnostics
11.3.8 Roche Enters into a Licensing agreement with QIAGEN
11.3.9 OvaGene Oncology Enters into Licensing Agreement with Bergen Teknologioverforing and Medinnova
11.3.10 bioMérieux Signs into a Co-development Agreement with GlaxoSmithKline
11.3.11 IDL Biotech Enters into a Licensing Agreement with Radim
11.3.12 Sysmex Europe Enters Into an Agreement with Adnagen
11.3.13 Immunogenetics Signs an Agreement with Adnagen
12 APPENDIX
12.1 Definition
12.2 Acronyms
12.3 Research Methodology
12.4 Secondary Research
12.5 Primary Research
12.6 Models
12.7 Forecasts
12.8 Expert Panels
12.9 GlobalData Consulting
12.10 Contact Us
12.11 Disclaimer 135
LIST OF TABLES
Table 1: Global Cancer Incidence, Most Common Cancers, by Sex, 2008
Table 2: Types of Tumor Markers
Table 3: Tumor Markers Market, Global, Revenue ($m), 2003 – 2010
Table 4: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017
Table 5: Increase in Specificity and Sensitivity, Multi-Marker Tests
Table 6: Cancer Incidence, by Geography, (%), 2008
Table 7: Tumor Markers Market, The US, Revenue ($m), 2003-2010
Table 8: Tumor Markers Market, The US, Revenue ($m), 2010-2017
Table 9: Tumor Markers Market, Canada, Revenue ($m), 2003-2010
Table 10: Tumor Markers Market, Canada, Revenue ($m), 2010-2017
Table 11: Tumor Markers Market, The UK, Revenue ($m), 2003-2010
Table 12: Tumor Markers Market, The UK, Revenue ($m), 2010-2017
Table 13: Tumor Markers Market, Germany, Revenue ($m), 2003-2010
Table 14: Tumor Markers Market, Germany, Revenue ($m), 2010-2017
Table 15: Tumor Markers Market, France, Revenue ($m), 2003-2010
Table 16: Tumor Markers Market, France, Revenue ($m), 2010-2017
Table 17: Tumor Markers Market, Italy, Revenue ($m), 2003-2010
Table 18: Tumor Markers Market, Italy, Revenue ($m), 2010-2017
Table 19: Tumor Markers Market, Spain, Revenue ($m), 2003-2010
Table 20: Tumor Markers Market, Spain, Revenue ($m), 2010-2017
Table 21: Tumor Markers Market, Japan, Revenue ($m), 2003-2010
Table 22: Tumor Markers Market, Japan, Revenue ($m), 2010-2017
Table 23: Tumor Markers Market, China, Revenue ($m), 2003-2010
Table 24: Tumor Markers Market, China, Revenue ($m), 2010-2017
Table 25: Tumor Markers Market, India, Revenue ($m), 2003-2010
Table 26: Tumor Markers Market, India, Revenue ($m), 2010-2017
Table 27: Tumor Markers Market, Australia, Revenue ($m), 2003-2010
Table 28: Tumor Markers Market, Australia, Revenue ($m), 2010-2017
Table 29: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010
Table 30: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017
Table 31: Tumor Markers Market, Global, Company Revenue ($m), 2010
Table 32: Abbott, Tumor Markers, Marketed Products
Table 33: Abbott, Tumor Markers, Pipeline Products
Table 34: F. Hoffman La Roche, Tumor Markers, Pipeline Products
Table 35: Fujirebio, Tumor Markers, Marketed Products
Table 36: bioMerieux, Tumor Markers, Marketed Products
Table 37: Beckman Coulter, Tumor Markers, Marketed Products
Table 38: Clarient, Tumor Markers, Marketed Products
Table 39: Siemens Healthcare, Tumor Markers, Marketed Products
Table 40: DiaSorin, Tumor Markers, Marketed Products
Table 41: QIAGEN, Tumor Markers, Marketed Products
Table 42: QIAGEN, Tumor Markers, Pipeline Products
Table 43: Xeptagen, Tumor Markers, Marketed Products
Table 44: Xeptagen, Tumor Markers, Pipeline Products
Table 45: Epi proColon-mSEPT9 - Clinical Trial
Table 46: Epi proColon-mSEPT9 - Clinical Trial
Table 47: Lung Cancer Screening Test - Clinical Trial
Table 48: DCP-IgM Liver Cancer Test - Clinical Trial
Table 49: AdnaTest BreastCancer - Clinical Trial
Table 50: AdnaTest BreastCancer - Clinical Trial
Table 51: AdnaTest BreastCancer - Clinical Trial
Table 52: AdnaTest BreastCancer - Clinical Trial
Table 53: AdnaTest ColonCancer - Clinical Trial
Table 54: ColoMark CCSA-4 Serum Assay - Clinical Trial
Table 55: Precision Profile-Prostate Cancer Early Detection Clinical Trial
Table 56: Diagnostic Marker-Colorectal Cancer - Clinical Trial
Table 57: Diagnostic Marker-Colorectal Cancer - Clinical Trial
Table 58: Semi-Quantitative Test for Uterine Cancer - Clinical Trial
Table 59: Biomarker mGSTP1-Prostate Cancer - Clinical Trial
Table 60: BCtect - Breast Cancer - Clinical Trial
Table 61: BronchoGen - Clinical Trial
Table 62: Early Stage Lung Cancer Diagnostic test - Clinical Trial
Table 63: P2V Prostate Cancer Test - Clinical Trial
Table 64: P2V Prostate Cancer Test - Clinical Trial
Table 65: Gastric Cancer Diagnostic Test - Clinical Trial
Table 66: Genefec III - Clinical Trial
Table 67: Genefec III - Clinical Trial
Table 68: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial
Table 69: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial
Table 70: NADiA ProsVue - Clinical Trial
Table 71: OncoDefender-CRC - Clinical Trial
Table 72: OvPlex 2nd Generation - Clinical Trial
Table 73: OvPlex 2nd Generation - Clinical Trial
Table 74: PROGENSA PCA3 Assay - Clinical Trial
Table 75: PROGENSA PCA3 Assay - Clinical Trial
Table 76: PROGENSA PCA3 Assay - Clinical Trial
Table 77: PROGENSA PCA3 Assay - Clinical Trial
Table 78: ProstaCheck - Clinical Trial
Table 79: PSP94 Immunoassay - Clinical Trial
Table 80: The Fermiscan Test - Clinical Trial
Table 81: The Fermiscan Test - Clinical Trial
Table 82: The Fermiscan Test - Clinical Trial
Table 83: Verisens Ultra-Sensitive PSA Assay - Clinical Trial 123
LIST OF FIGURES
Figure 1: Classification of Cancers, by Tissue of Origin
Figure 2: Most Common Types of Cancers, Classification by Primary Site of Origin
Figure 3: Cancer Incidence Rate, Global, 2008
Figure 4: Cancer Incidence, Global, Most Common Cancers, by Sex, 2008
Figure 5: List Of Common Tumor Markers Used for Detection of Multiple Cancers, 2010
Figure 6: Tumor Markers Market, Global, Revenue($m), 2003 – 2010
Figure 7: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017
Figure 8: Tumor Markers, Market Dynamics
Figure 9: Cancer Incidence, by Geography, (%), 2008
Figure 10: Healthcare Spending Growth Rate (%), Asia-Pacific, 2007-2008
Figure 11: Tumor Markers Market, The US, Revenue ($m), 2003-2010
Figure 12: Tumor Markers Market, The US, Revenue ($m), 2010-2017
Figure 13: Tumor Markers Market, Canada, Revenue ($m), 2003-2010
Figure 14: Tumor Markers Market, Canada, Revenue ($m), 2010-2017
Figure 15: Tumor Markers Market, The UK, Revenue ($m), 2003-2010
Figure 16: Tumor Markers Market, The UK, Revenue ($m), 2010-2017
Figure 17: Tumor Markers Market, Germany, Revenue ($m), 2003-2010
Figure 18: Tumor Markers Market, Germany, Revenue ($m), 2010-2017
Figure 19: Tumor Markers Market, France, Revenue ($m), 2003-2010
Figure 20: Tumor Markers Market, France, Revenue ($m), 2010-2017
Figure 21: Tumor Markers Market, Italy, Revenue ($m), 2003-2010
Figure 22: Tumor Markers Market, Italy, Revenue ($m), 2010-2017
Figure 23: Tumor Markers Market, Spain, Revenue ($m), 2003-2010
Figure 24: Tumor Markers Market, Spain, Revenue ($m), 2010-2017
Figure 25: Tumor Markers Market, Japan, Revenue ($m), 2003-2010
Figure 26: Tumor Markers Market, Japan, Revenue ($m), 2010-2017
Figure 27: Tumor Markers Market, China, Revenue ($m), 2003-2010
Figure 28: Tumor Markers Market, China, Revenue ($m), 2010-2017
Figure 29: Tumor Markers Market, India, Revenue ($m), 2003-2010
Figure 30: Tumor Markers Market, India, Revenue ($m), 2010-2017
Figure 31: Tumor Markers Market, Australia, Revenue ($m), 2003-2010
Figure 32: Tumor Markers Market, Australia, Revenue ($m), 2010-2017
Figure 33: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010
Figure 34: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017
Figure 35: Tumor Markers Market, Global, Key Company Share (%), 2010
Figure 36: SWOT Analysis, Abbott
Figure 37: SWOT Analysis, F. Hoffman La Roche
Figure 38: SWOT Analysis, Fujirebio, Inc.
Figure 39: SWOT Analysis, bioMérieux SA
Figure 40: SWOT Analysis, Beckman Coulter
Figure 41: Tumor Markers, Pipeline Products by Development Stage, Global, 2010
Figure 42: Tumor Markers, Pipeline Products by Therapy Area, Global, 2010 73
COMPANIES MENTIONED
Abbott Laboratories (Abbott)
F. Hoffman-La Roche
Fujirebio Inc.
bioMérieux S.A.
Beckman Coulter
Clarient Inc.
Siemens Healthcare
DiaSorin SpA
QIAGEN N.V.
Xeptagen SpA
1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 GlobalData Report Guidance
3 DISEASE OVERVIEW: CANCER
3.1 Etiology
3.2 Types of cancers
3.2.1 Classification by Histology
3.2.2 Cancer Types by Site
3.3 Cancer Signs and Symptoms
3.4 Cancer Diagnosis
3.5 Epidemiology
4 TUMOR MARKERS OVERVIEW
4.1 Tumor Markers: Technology Overview
4.1.1 Introduction
4.1.2 Types of Tumor Markers
4.1.3 Applications
5 TUMOR MARKERS: GLOBAL MARKET CHARACTERIZATION
5.1 Tumor Markers Market, Global, Revenue ($m), Historic, 2003 − 2010
5.2 Tumor Markers Market, Global, Revenue ($m), Forecast, 2010 − 2017
5.3 Tumor Markers, Key Market Trends
5.3.1 Increasing Investments by Private Equity (PE) /Venture Capital (VC) Firms in Startups is Driving Innovation and Market Growth
5.3.2 Novel Tumor Markers Makes Diagnostic Test for Ovarian Cancer More Efficient
5.4 Tumor Markers, Market Dynamics
5.4.1 Market Drivers
5.4.2 Market Restraints
5.5 Tumor Markers Market, Opportunities and Unmet Needs
5.5.1 Opportunities: Highly Fragmented Market to Provide a Significant Opportunity for Big Tumor Marker Manufacturers
5.5.2 Unmet Needs
6 TUMOR MARKERS MARKET, BY COUNTRY, REVENUE ($M), 2003 – 2017
6.1 Tumor Markers Market, The US, Revenue ($m), Historic, 2003–2010
6.2 Tumor Markers Market, The US, Revenue ($m), Forecast, 2010–2017
6.3 Tumor Markers Market, Canada, Revenue ($m), Historic, 2003–2010
6.4 Tumor Markers Market, Canada, Revenue ($m), Forecast, 2010–2017
6.5 Tumor Markers Market, The UK, Revenue ($m), Historic, 2003-2010
6.6 Tumor Markers Market, The UK, Revenue ($m), Forecast, 2010-2017
6.7 Tumor Markers Market, Germany, Revenue ($m), Historic, 2003-2010
6.8 Tumor Markers Market, Germany, Revenue ($m), Forecast, 2010-2017
6.9 Tumor Markers Market, France, Revenue ($m), Historic, 2003- 2010
6.10 Tumor Markers Market, France, Revenue ($m), Forecast, 2010-2017
6.11 Tumor Markers Market, Italy, Revenue ($m), Historic, 2003-2010
6.12 Tumor Markers Market, Italy, Revenue ($m), Forecast, 2010-2017
6.13 Tumor Markers Market, Spain, Revenue ($m), Historic, 2003-2010
6.14 Tumor Markers Market, Spain, Revenue ($m), Forecast, 2010-2017
6.15 Tumor Markers Market, Japan, Revenue ($m), Historic, 2003-2010
6.16 Tumor Markers Market, Japan, Revenue ($m), Forecast, 2010-2017
6.17 Tumor Markers Market, China, Revenue ($m), Historic, 2003-2010
6.18 Tumor Markers Market, China, Revenue ($m), Forecast, 2010-2017
6.19 Tumor Markers Market, India, Revenue ($m), Historic, 2003-2010
6.20 Tumor Markers Market, India, Revenue ($m), Forecast, 2010-2017
6.21 Tumor Markers Market, Australia, Revenue ($m), Historic, 2003-2010
6.22 Tumor Markers Market, Australia, Revenue ($m), Forecast, 2010-2017
6.23 Tumor Markers Market, Brazil, Revenue ($m), Historic, 2003-2010
6.24 Tumor Markers Market, Brazil, Revenue ($m), Forecast, 2010-2017
7 TUMOR MARKERS MARKET: COMPETITIVE LANDSCAPE
7.1 Tumor Markers Market, Key Company Share (%), 2010
7.2 Abbott Laboratories (Abbott)
7.2.1 Company Overview
7.2.2 Marketed Products
7.2.3 Pipeline Products
7.2.4 SWOT Analysis
7.3 F. Hoffman-La Roche
7.3.1 Company Overview
7.3.2 Marketed Products
7.3.3 Pipeline Products
7.3.4 SWOT Analysis
7.4 Fujirebio Inc.
7.4.1 Company Overview
7.4.2 Marketed Products
7.4.3 SWOT Analysis
7.5 bioMérieux S.A.
7.5.1 Company Overview
7.5.2 Marketed Products
7.5.3 Pipeline Products
7.5.4 SWOT Analysis
7.6 Beckman Coulter
7.6.1 Company Overview
7.6.2 Marketed Products
7.6.3 Pipeline Products
7.6.4 SWOT Analysis
8 GLOBAL TUMOR MARKERS MARKET: OTHER MAJOR COMPANIES
8.1 Clarient Inc.
8.1.1 Company Overview
8.1.2 Marketed Products
8.1.3 Pipeline Products
8.2 Siemens Healthcare
8.2.1 Company Overview
8.2.2 Marketed Products
8.2.3 Pipeline Products
8.3 DiaSorin SpA
8.3.1 Company Overview
8.3.2 Marketed Products
8.4 QIAGEN N.V.
8.4.1 Company Overview
8.4.2 Marketed Products
8.4.3 Pipeline Products
8.5 Xeptagen SpA
8.5.1 Company Overview
8.5.2 Marketed Products
8.5.3 Pipeline Products
9 GLOBAL TUMOR MARKERS MARKET: STRATEGIC PIPELINE ASSESSMENT
9.1 Tumor Markers Market: Pipeline Products summary
9.2 Tumor Markers, Pipeline Products by Development Stage, Global, 2010
9.3 Tumor Markers Market, Pipeline Products by Therapy Area, Global, 2010
10 TUMOR MARKERS- IMPORTANT PIPELINE PRODUCTS BY COMPANY
10.1 F.Hoffman La Roche'
10.1.1 Integrated Modular Analytics cyfra21-1/NSE Test
10.2 bioMérieux S.A.
10.2.1 EHT Dx 12
10.2.2 EHT Dx 13
10.3 Siemens Healthcare
10.4 Epigenomics AG
10.4.1 Epi proColon-mSEPT9
10.4.2 Lung Cancer Screening Test
10.5 Xeptagen SpA
10.5.1 DCP-IgM Liver cancer Test
10.5.2 Multi-Marker biochip
10.5.3 SCCA–IgM Pulmonary cancer test
10.6 AdnaGen Inc.
10.6.1 AdnaTest BreastCancer
10.6.2 AdnaTest ColonCancer
10.7 QIAGEN N.V.
10.7.1 BRaf Test-Colon Cancer
10.7.2 EGFR Assay-Lung Cancer
10.8 Quanterix corporation
10.8.1 AccuPSA Test
10.9 Rosetta Genomics
10.9.1 miRNA Based Diagnostic Test For Breast Cancer
10.10 Oncomethylome Sciences
10.10.1 Cervical cancer diagnostic test
10.10.2 InformDx - Lung Cancer test
10.11 Onconome Inc.
10.11.1 ColoMark CCSA-4 Serum Assay
10.12 Source MDx
10.12.1 Aggressive Cancer Stratification–Prostate Cancer
10.12.2 Precision Profile-Prostate Cancer Early Detection
10.13 Trovagene, Inc.
10.13.1 AML/NPM1-Bone Marrow/Blood
10.14 Mitomics Inc.
10.14.1 Bladder Cancer-Diagnostic Test
10.15 Glycozyme.
10.15.1 Breast cancer Biomarker Assay
10.16 Neogenix Oncology Corporation
10.16.1 Diagnostic Marker-Colorectal Cancer
10.17 Exiqon A/S
10.17.1 Colon Cancer Recurrence Test
10.17.2 miRNA Test-Endometrial Cancer
10.18 China Sky One Medical, Inc.
10.18.1 Semi-quantitative test for uterine cancer
10.18.2 Liver Cancer Diagnostic Kit
10.19 Advanced Cell Diagnostics
10.19.1 Breast Cancer Test
10.20 Zetiq Technologies Ltd
10.20.1 CellDetect for Cervical Cancer
10.21 Biomoda, Inc.
10.21.1 Cypath-bladder cancer diagnostic assay
10.22 Predictive Biosciences. Inc.
10.22.1 Biomarker mGSTP1-Prostate Cancer
10.23 Power3 Medical Products, Inc
10.23.1 BC-SeraPro Assay
10.24 DiaGenic ASA
10.24.1 BCtect
10.24.2 Breast Cancer Screening Test
10.25 Protagen AG
10.25.1 Breast Cancer-Early Diagnosis assay
10.26 BioMarCare Technologies Ltd.
10.26.1 Breast PARpanel
10.27 Akers Biosciences, Inc.
10.27.1 Breath PulmoHealth Check
10.28 Allegro Diagnostics, Inc.
10.28.1 BronchoGen
10.29 MabCure, Inc.
10.29.1 Diagnostic Test-Breast Carcinoma
10.30 Cangen Biotechnologies, Inc.
10.30.1 Early Stage Lung Cancer Diagnostic test
10.31 Exosome Diagnostics, Inc.
10.31.1 EGFR Cancer Gene Mutation test
10.32 Exagen Diagnostics, Inc.
10.32.1 eXagenBC(ER/PR+)
10.33 Martell Biosystems, Inc
10.33.1 FACTT-Breast cancer assay
10.34 Miraculins Inc.
10.34.1 P2V Prostate Cancer Test
10.34.2 Gastric Cancer Diagnostic Test
10.35 NorDiag ASA
10.35.1 Genefec III
10.36 A&G Pharmaceutical, Inc.
10.36.1 GP88 Blood Diagnostic Test
10.37 Expression Pathology Inc.
10.37.1 HER2 Assay for Breast Cancer
10.38 Milagen, Inc
10.38.1 Immunoassay - Colon Cancer
10.39 IncellDx, Inc.
10.39.1 IncellDx Breast Cancer Test
10.40 Gene Express, Inc.
10.40.1 Lung Cancer Diagnostic Assay
10.41 GenomicTree Inc
10.41.1 MDScan Cervical Cancer Screening Test
10.42 BIOCRATES Life Sciences AG
10.42.1 Metabolomic Biomarker Assay-Cancer
10.43 Health Discovery Corporation
10.43.1 Molecular diagnostic test-pancreatic cancer
10.44 Gene Express, Inc.
10.44.1 Molecular Diagnostic Tests for Bladder Cancer
10.45 IRIS International, Inc.
10.45.1 NADiA ProsVue
10.46 Everist Genomics, Inc.
10.46.1 OncoDefender-CRC
10.47 Orion Genomics LLC
10.47.1 Orion Colorectal Cancer Risk Test
10.48 Correlogic Systems, Inc.
10.48.1 OvaCheck
10.49 Arrayit Corporation
10.49.1 OvaDx
10.50 Protagen AG
10.50.1 Ovarian Cancer-Early Diagnosis Assay
10.51 HealthLinx Limited
10.51.1 OvPlex 2nd Generation
10.52 Strategic Diagnostics Inc.
10.52.1 Pancreatic Cancer Assay
10.53 HistoRx, Inc.
10.53.1 PI3K Multimarker Assay
10.53.2 PROGENSA PCA3 Assay
10.54 Correlogic Systems, Inc.
10.54.1 ProstaCheck
10.55 AnalizaDx, LLC
10.55.1 Prostate Cancer Biomarker Test
10.56 Ambrilia Biopharma Inc.
10.56.1 PSP94 Immunoassay
10.57 BioCurex Inc
10.57.1 RECAF Blood Test
10.58 Fermiscan Holdings Limited
10.58.1 The Fermiscan Test
10.59 Nanosphere, Inc.
10.59.1 Verisens Ultra-Sensitive PSA Assay
11 GLOBAL TUMOR MARKERS MARKET: DEALS LANDSCAPE
11.1 Global Tumor Markers Market: Deals Overview
11.2 Global Tumor Markers Market: Key Acquisitions
11.2.1 Vivakor Enters Into Memorandum of Understanding to Merge with Resolution Biomedical
11.2.2 GE Healthcare Acquires Clarient
11.2.3 Danaher to Acquire Beckman Coulter Inc
11.2.4 Myriad Genetics to Acquire Novel Technology from Melanoma Diagnostics
11.2.5 Fujirebio Acquires Innogenetics from Abbott Laboratories
11.3 Global Tumor Markers Market: Partnership Deals
11.3.1 UCL Business Enters Into a Licensing Agreement with Becton Dickinson
11.3.2 Rosetta Genomics Enters Into an Agreement with Carmel Medical Center
11.3.3 Transgene Signs an Agreement with Beckman Coulter Inc
11.3.4 Neogenix Oncology Enters an Agreement with IRCCS San Raffaele Pisana
11.3.5 Vermillion Enters Into an Agreement with Quest Diagnostics
11.3.6 BioMérieux Enters into a Co-Development Agreement with Biocartis
11.3.7 Epigenomics Enters Into an Agreement with Pronto Diagnostics
11.3.8 Roche Enters into a Licensing agreement with QIAGEN
11.3.9 OvaGene Oncology Enters into Licensing Agreement with Bergen Teknologioverforing and Medinnova
11.3.10 bioMérieux Signs into a Co-development Agreement with GlaxoSmithKline
11.3.11 IDL Biotech Enters into a Licensing Agreement with Radim
11.3.12 Sysmex Europe Enters Into an Agreement with Adnagen
11.3.13 Immunogenetics Signs an Agreement with Adnagen
12 APPENDIX
12.1 Definition
12.2 Acronyms
12.3 Research Methodology
12.4 Secondary Research
12.5 Primary Research
12.6 Models
12.7 Forecasts
12.8 Expert Panels
12.9 GlobalData Consulting
12.10 Contact Us
12.11 Disclaimer 135
LIST OF TABLES
Table 1: Global Cancer Incidence, Most Common Cancers, by Sex, 2008
Table 2: Types of Tumor Markers
Table 3: Tumor Markers Market, Global, Revenue ($m), 2003 – 2010
Table 4: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017
Table 5: Increase in Specificity and Sensitivity, Multi-Marker Tests
Table 6: Cancer Incidence, by Geography, (%), 2008
Table 7: Tumor Markers Market, The US, Revenue ($m), 2003-2010
Table 8: Tumor Markers Market, The US, Revenue ($m), 2010-2017
Table 9: Tumor Markers Market, Canada, Revenue ($m), 2003-2010
Table 10: Tumor Markers Market, Canada, Revenue ($m), 2010-2017
Table 11: Tumor Markers Market, The UK, Revenue ($m), 2003-2010
Table 12: Tumor Markers Market, The UK, Revenue ($m), 2010-2017
Table 13: Tumor Markers Market, Germany, Revenue ($m), 2003-2010
Table 14: Tumor Markers Market, Germany, Revenue ($m), 2010-2017
Table 15: Tumor Markers Market, France, Revenue ($m), 2003-2010
Table 16: Tumor Markers Market, France, Revenue ($m), 2010-2017
Table 17: Tumor Markers Market, Italy, Revenue ($m), 2003-2010
Table 18: Tumor Markers Market, Italy, Revenue ($m), 2010-2017
Table 19: Tumor Markers Market, Spain, Revenue ($m), 2003-2010
Table 20: Tumor Markers Market, Spain, Revenue ($m), 2010-2017
Table 21: Tumor Markers Market, Japan, Revenue ($m), 2003-2010
Table 22: Tumor Markers Market, Japan, Revenue ($m), 2010-2017
Table 23: Tumor Markers Market, China, Revenue ($m), 2003-2010
Table 24: Tumor Markers Market, China, Revenue ($m), 2010-2017
Table 25: Tumor Markers Market, India, Revenue ($m), 2003-2010
Table 26: Tumor Markers Market, India, Revenue ($m), 2010-2017
Table 27: Tumor Markers Market, Australia, Revenue ($m), 2003-2010
Table 28: Tumor Markers Market, Australia, Revenue ($m), 2010-2017
Table 29: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010
Table 30: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017
Table 31: Tumor Markers Market, Global, Company Revenue ($m), 2010
Table 32: Abbott, Tumor Markers, Marketed Products
Table 33: Abbott, Tumor Markers, Pipeline Products
Table 34: F. Hoffman La Roche, Tumor Markers, Pipeline Products
Table 35: Fujirebio, Tumor Markers, Marketed Products
Table 36: bioMerieux, Tumor Markers, Marketed Products
Table 37: Beckman Coulter, Tumor Markers, Marketed Products
Table 38: Clarient, Tumor Markers, Marketed Products
Table 39: Siemens Healthcare, Tumor Markers, Marketed Products
Table 40: DiaSorin, Tumor Markers, Marketed Products
Table 41: QIAGEN, Tumor Markers, Marketed Products
Table 42: QIAGEN, Tumor Markers, Pipeline Products
Table 43: Xeptagen, Tumor Markers, Marketed Products
Table 44: Xeptagen, Tumor Markers, Pipeline Products
Table 45: Epi proColon-mSEPT9 - Clinical Trial
Table 46: Epi proColon-mSEPT9 - Clinical Trial
Table 47: Lung Cancer Screening Test - Clinical Trial
Table 48: DCP-IgM Liver Cancer Test - Clinical Trial
Table 49: AdnaTest BreastCancer - Clinical Trial
Table 50: AdnaTest BreastCancer - Clinical Trial
Table 51: AdnaTest BreastCancer - Clinical Trial
Table 52: AdnaTest BreastCancer - Clinical Trial
Table 53: AdnaTest ColonCancer - Clinical Trial
Table 54: ColoMark CCSA-4 Serum Assay - Clinical Trial
Table 55: Precision Profile-Prostate Cancer Early Detection Clinical Trial
Table 56: Diagnostic Marker-Colorectal Cancer - Clinical Trial
Table 57: Diagnostic Marker-Colorectal Cancer - Clinical Trial
Table 58: Semi-Quantitative Test for Uterine Cancer - Clinical Trial
Table 59: Biomarker mGSTP1-Prostate Cancer - Clinical Trial
Table 60: BCtect - Breast Cancer - Clinical Trial
Table 61: BronchoGen - Clinical Trial
Table 62: Early Stage Lung Cancer Diagnostic test - Clinical Trial
Table 63: P2V Prostate Cancer Test - Clinical Trial
Table 64: P2V Prostate Cancer Test - Clinical Trial
Table 65: Gastric Cancer Diagnostic Test - Clinical Trial
Table 66: Genefec III - Clinical Trial
Table 67: Genefec III - Clinical Trial
Table 68: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial
Table 69: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial
Table 70: NADiA ProsVue - Clinical Trial
Table 71: OncoDefender-CRC - Clinical Trial
Table 72: OvPlex 2nd Generation - Clinical Trial
Table 73: OvPlex 2nd Generation - Clinical Trial
Table 74: PROGENSA PCA3 Assay - Clinical Trial
Table 75: PROGENSA PCA3 Assay - Clinical Trial
Table 76: PROGENSA PCA3 Assay - Clinical Trial
Table 77: PROGENSA PCA3 Assay - Clinical Trial
Table 78: ProstaCheck - Clinical Trial
Table 79: PSP94 Immunoassay - Clinical Trial
Table 80: The Fermiscan Test - Clinical Trial
Table 81: The Fermiscan Test - Clinical Trial
Table 82: The Fermiscan Test - Clinical Trial
Table 83: Verisens Ultra-Sensitive PSA Assay - Clinical Trial 123
LIST OF FIGURES
Figure 1: Classification of Cancers, by Tissue of Origin
Figure 2: Most Common Types of Cancers, Classification by Primary Site of Origin
Figure 3: Cancer Incidence Rate, Global, 2008
Figure 4: Cancer Incidence, Global, Most Common Cancers, by Sex, 2008
Figure 5: List Of Common Tumor Markers Used for Detection of Multiple Cancers, 2010
Figure 6: Tumor Markers Market, Global, Revenue($m), 2003 – 2010
Figure 7: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017
Figure 8: Tumor Markers, Market Dynamics
Figure 9: Cancer Incidence, by Geography, (%), 2008
Figure 10: Healthcare Spending Growth Rate (%), Asia-Pacific, 2007-2008
Figure 11: Tumor Markers Market, The US, Revenue ($m), 2003-2010
Figure 12: Tumor Markers Market, The US, Revenue ($m), 2010-2017
Figure 13: Tumor Markers Market, Canada, Revenue ($m), 2003-2010
Figure 14: Tumor Markers Market, Canada, Revenue ($m), 2010-2017
Figure 15: Tumor Markers Market, The UK, Revenue ($m), 2003-2010
Figure 16: Tumor Markers Market, The UK, Revenue ($m), 2010-2017
Figure 17: Tumor Markers Market, Germany, Revenue ($m), 2003-2010
Figure 18: Tumor Markers Market, Germany, Revenue ($m), 2010-2017
Figure 19: Tumor Markers Market, France, Revenue ($m), 2003-2010
Figure 20: Tumor Markers Market, France, Revenue ($m), 2010-2017
Figure 21: Tumor Markers Market, Italy, Revenue ($m), 2003-2010
Figure 22: Tumor Markers Market, Italy, Revenue ($m), 2010-2017
Figure 23: Tumor Markers Market, Spain, Revenue ($m), 2003-2010
Figure 24: Tumor Markers Market, Spain, Revenue ($m), 2010-2017
Figure 25: Tumor Markers Market, Japan, Revenue ($m), 2003-2010
Figure 26: Tumor Markers Market, Japan, Revenue ($m), 2010-2017
Figure 27: Tumor Markers Market, China, Revenue ($m), 2003-2010
Figure 28: Tumor Markers Market, China, Revenue ($m), 2010-2017
Figure 29: Tumor Markers Market, India, Revenue ($m), 2003-2010
Figure 30: Tumor Markers Market, India, Revenue ($m), 2010-2017
Figure 31: Tumor Markers Market, Australia, Revenue ($m), 2003-2010
Figure 32: Tumor Markers Market, Australia, Revenue ($m), 2010-2017
Figure 33: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010
Figure 34: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017
Figure 35: Tumor Markers Market, Global, Key Company Share (%), 2010
Figure 36: SWOT Analysis, Abbott
Figure 37: SWOT Analysis, F. Hoffman La Roche
Figure 38: SWOT Analysis, Fujirebio, Inc.
Figure 39: SWOT Analysis, bioMérieux SA
Figure 40: SWOT Analysis, Beckman Coulter
Figure 41: Tumor Markers, Pipeline Products by Development Stage, Global, 2010
Figure 42: Tumor Markers, Pipeline Products by Therapy Area, Global, 2010 73
COMPANIES MENTIONED
Abbott Laboratories (Abbott)
F. Hoffman-La Roche
Fujirebio Inc.
bioMérieux S.A.
Beckman Coulter
Clarient Inc.
Siemens Healthcare
DiaSorin SpA
QIAGEN N.V.
Xeptagen SpA